Web Results

www.pacermonitor.com/public/case/22965865/MORRISON_v_ASTRAZENECA_PHARMACEUTICALS_LP_et_al

Nov 10, 2017 ... MORRISON v. ASTRAZENECA PHARMACEUTICALS LP et al (2:17-cv-11501), New Jersey District Court, Filed: 11/10/2017 - PacerMonitor Mobile Federal and Bankruptcy Court PACER Dockets.

law.justia.com/cases/federal/district-courts/missouri/mowdce/4:2016cv01106/130450/52

Foster v. AstraZeneca Pharmaceuticals LP et al, No. 4:2016cv01106 - Document 52 (W.D. Mo. 2017) case opinion from the Western District of Missouri U.S. Federal District Court.

www.ippractice.ca/litigation-statistics/intellectual-property-proceedings-in-federal-court-for-2017

T-285-17, OAKVILLE STAMPING & BENDING LIMITED v. TOMLIN INDUSTRIES (2000) INC. ET AL. Patent Infringement, 2017-02-28, Gowling WLG (Canada) LLP; ... INC v. CANADIAN ENERGY SERVICES L.P., Trade Mark – Appeal of a decision of the Registrar, 2017-03-16, Sim Ashton & McKay LLP; JONES, ANDREW;.

www.erisacase.com/faqs

As soon as you encounter trouble seeking ERISA benefits, you should seek the advice of an ERISA attorney. Your rights could be impacted if you delay.

www.jacionline.org/article/S0091-6749(13)00314-X/pdf

Apr 13, 2013 ... Supported by Teva Pharmaceuticals Limited of Petach Tikva, Israel. Disclosure of ... AstraZeneca), Merck, newMentor, NKT Therapeutics, Ono Pharmaceuticals, Pulmatrix, .... SABA: Short-acting b-agonist. UK: United Kingdom. US: United States. J ALLERGY CLIN IMMUNOL. JULY 2013. 46 COLICE ET AL ...

www.jacionline.org/article/S0091-6749(10)01042-0/pdf

Aug 9, 2010 ... Nicolas Roche, MD, PhD,g Alison Chisholm, MSc,b Elizabeth V. Hillyer, DVM,b Linda Kemp, BSc,b Amanda J. Lee, PhD,h. Julie von Ziegenweidt ..... of baseline characteristics between the matched cohorts. Baseline differences between. J ALLERGY CLIN IMMUNOL. SEPTEMBER 2010. 512 PRICE ET AL ...

www.nejm.org/doi/full/10.1056/NEJMoa022207

May 22, 2003 ... Editor's Note: The scientific reports by Hwang et al.1,2 that are described in this article were retracted by Science on January 12, 2006. See Snyder and ..... Dr. Szapary reports having received lecture fees from AstraZeneca and Kos Pharmaceuticals and grant support from AstraZeneca. Dr. Klein reports ...

www.ajconline.org/article/S0002-9149(15)01350-8/pdf

Death, MI, uTVR. 28. NO. Chan et al. 15,. 2003. Post-hoc analysis of the. TARGET trial. Clopidogrel. 300 mg (upstream) vs 300 mg. (downstream) on top of GPI. 2.1 ... DAPT ¼ dual antiplatelet therapy; EVENT ¼ Evaluation of Drug- Eluting Stents and Ischemic Events; GPI ¼ glycoprotein IIb/IIIa inhibitors; ISAR- REACT ¼ ...

www.law360.com/cases/4dd67c849043432662000004

Jul 27, 2016 ... Parties, docket activity and news coverage of federal case Lyondell Chemical Company, case number 1:09-bk-10023, from New York Southern Court.